Related Experiment Videos
Prognostic relevance of morphological classification in multiple myeloma
H Murakami1, K Nemoto, M Sawamura
1Third Department of Internal Medicine, Gunma University School of Medicine, Japan.
Acta Haematologica
|January 1, 1992
Summary
This study re-evaluates multiple myeloma subtypes, finding plasmablastic myeloma is not a poor prognostic factor. Immature and plasmablastic subtypes were linked to poorer outcomes compared to mature and intermediate types.
Area of Science:
- Hematology
- Oncology
- Cancer Research
Background:
- Multiple myeloma is classified into subtypes based on plasma cell morphology.
- Greipp's criteria categorize subtypes as mature, intermediate, immature, or plasmablastic.
- The prognostic significance of the plasmablastic subtype requires further investigation.
Purpose of the Study:
- To investigate the prognostic value of different multiple myeloma subtypes.
- To compare survival times and clinical characteristics between subtypes.
- To determine if plasmablastic and immature subtypes are unfavorable prognostic factors.
Main Methods:
- Classification of 122 multiple myeloma patients into mature, intermediate, immature, or plasmablastic subtypes using Greipp's criteria.
- Analysis of survival times and clinical parameters across subtypes.
- Statistical comparison of clinical features between prognostic groups.
Main Results:
- Contrary to previous reports, plasmablastic myeloma did not show significantly shorter survival.
- Mature plus intermediate myeloma subtypes had significantly longer survival than immature plus plasmablastic subtypes.
- Significant differences between these groups included sex, clinical stage, thrombocytopenia, bone marrow plasmacytosis, renal insufficiency, bone destruction, and treatment response.
Conclusions:
- Immature and plasmablastic multiple myeloma subtypes are suspected to be unfavorable prognostic factors.
- Specific clinical features differentiate prognostic groups, impacting patient outcomes.
- Further research is warranted to fully elucidate the role of these subtypes in multiple myeloma prognosis.